"NLRP3 is a biologically relevant target with significant potential across a number of liver, kidney, and cardiometabolic diseases," according to Karin Conde-Knape, Novo Nordisk's head of global ...

NodThera’s NLRP3 inhibitor has already proved its worth against Novo Nordisk’s blockbuster obesity drug in preclinical trials. Now, an early readout from a study in humans with obesity has ...

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio ...

The Novo Nordisk ... mentorship from Novo Nordisk, we are in a stronger position to advance HT-6184 toward clinical development." Halia's HT-6184 is a first-in-class NEK7/NLRP3 inflammasome ...